Document is current
Any future updates will be listed below
-
Authors
Dreyfuss, Jonathan M. https://orcid.org/0000-0001-7242-3991
Yuchi, Yixing https://orcid.org/0000-0002-9439-0913
Dong, Xuehong
Efthymiou, Vissarion https://orcid.org/0000-0003-4327-7977
Pan, Hui https://orcid.org/0000-0001-5748-7217
Simonson, Donald C. https://orcid.org/0000-0002-4670-6290
Vernon, Ashley
Halperin, Florencia
Aryal, Pratik https://orcid.org/0000-0001-6443-8974
Konkar, Anish
Sebastian, Yinong
Higgs, Brandon W.
Grimsby, Joseph
Rondinone, Cristina M.
Kasif, Simon https://orcid.org/0000-0003-3297-9914
Kahn, Barbara B. https://orcid.org/0000-0002-4027-0000
Foster, Kathleen
Seeley, Randy https://orcid.org/0000-0002-3721-5625
Goldfine, Allison https://orcid.org/0000-0002-0345-1048
Djordjilović, Vera https://orcid.org/0000-0002-7670-3111
Patti, Mary Elizabeth https://orcid.org/0000-0002-8163-3429
-
Funding
Funding for this research was provided by:
MedImmune
- License Information
-
More Information
Article History
Received: 10 February 2020
Accepted: 11 November 2021
First Online: 29 November 2021
Competing interests
: For the parent study (SLIMM-T2D) from which samples were derived for analysis in the current study, D.S., A.V., F.H., and A.B.G. received unrestricted funding from the Herbert Graetz Fund and from Covidien, to support surgical procedures for research participants with BMI 30-35 (not covered by insurance). Some supplies for the SLIMM-T2D clinical study were received from Lifescan, a division of Johnson and Johnson, Nestle Inc, and Novo Nordisk. M.E.P. received unrestricted investigator-initiated research grant funding from Medimmune to support the present work, and funding to support assay costs from SomaLogic. ABG served on advisory boards for Baranova, and Kowa. DCS received funds from PCORI and is a stock/shareholder of GI Windows. A.K., B.H., C.M.R., J.G., and Y.S. were employees of Medimmune when the work was initiated. Y.Y. is now employed at Vertex, F.H. at Form Health, A.K. at Sanofi, B.H. at Immunocore, J.G. at AstraZeneca, and A.B.G. at Novartis Institutes of Biomedical Research. All other authors declare no competing interests.
